Johnson & Johnson Stock Price Experiences Significant Fluctuations
Johnson & Johnson’s stock price has declined by over 7% in a single day, reaching its lowest level since late February. This decline occurred on [date] and marks a significant drop in the company’s stock value.
Reasons for Decline
The decline in Johnson & Johnson’s stock price is attributed to several factors, including:
- Rejection of a $10 billion plan to settle thousands of lawsuits alleging its talc-based products caused cancer
- Uncertainty surrounding import tariffs in the US
Upcoming Acquisition
Johnson & Johnson is expected to complete its acquisition of Intra-Cellular Therapies, which may accelerate the company’s sales growth in 2025.
Rating Reaffirmed
Guggenheim has reaffirmed its “neutral” rating for Johnson & Johnson, indicating that the company’s stock price may stabilize in the near future.